Who Exports Naproxen from India — 192 Suppliers Behind a $133.8M Market
India's naproxen export market is supplied by 192 active exporters who collectively shipped $133.8M across 3,414 shipments. MYLAN LABORATORIES LIMITED leads with a 17.4% market share, followed by UNICHEM LABORATORIES LIMITED and GLENMARK PHARMACEUTICALS LIMITED. The top 5 suppliers together control 60.2% of total export value, reflecting a concentrated market structure.
Top Naproxen Exporters from India — Ranked by Export Value
MYLAN LABORATORIES LIMITED is the leading naproxen exporter from India, holding a 17.4% share of the $133.8M market across 3,414 shipments from 192 exporters. The top 5 suppliers — MYLAN LABORATORIES LIMITED, UNICHEM LABORATORIES LIMITED, GLENMARK PHARMACEUTICALS LIMITED, AMNEAL PHARMACEUTICALS PRIVATE LIMITED, GRANULES INDIA LIMITED — collectively control 60.2% of total export value, indicating a moderately concentrated market. Individual shares are: MYLAN LABORATORIES LIMITED (17.4%), UNICHEM LABORATORIES LIMITED (16.2%), GLENMARK PHARMACEUTICALS LIMITED (10.5%), AMNEAL PHARMACEUTICALS PRIVATE LIMITED (9.7%), GRANULES INDIA LIMITED (6.3%).
Top Naproxen Exporters from India
Ranked by export value · 192 active suppliers · Indian Customs (DGFT) data
| # | Supplier & Formulations | Value | Ctry. | Share |
|---|---|---|---|---|
| 1 | MYLAN LABORATORIES LIMITED MYLAN NAPROXEN / ESOMEPRAZOLE MR 500 MGNAPROXEN SODIUM TABLETS USP 220MG TABSNAPROXEN ACCORD 500MG TAB | $23.3M | 3 | 17.4% |
| 2 | UNICHEM LABORATORIES LIMITED NALGESIN TABLETS 550MG (NAPROXEN SODIUMNALGESIN TABLETS 275MG (NAPROXEN SODIUMNALGESIN TABLETS 550MG NAPROXEN SODIUM | $21.7M | 1 | 16.2% |
| 3 | GLENMARK PHARMACEUTICALS LIMITED NAPROXEN TAB 500MG 500NAPROXEN AND ESOMEPRAZOLE MAGNESIUM DELA | $14.1M | 2 | 10.5% |
| 4 | AMNEAL PHARMACEUTICALS PRIVATE LIMITED NAPROXEN TAB 500MG 500NAPROXEN AND ESOMEPRAZOLE MAGNESIUM DELA | $13.0M | 1 | 9.7% |
| 5 | GRANULES INDIA LIMITED NAPROXEN TAB 500MG 500MYLAN NAPROXEN / ESOMEPRAZOLE MR 500 MGNAPROXEN AND ESOMEPRAZOLE MAGNESIUM DELA | $8.5M | 2 | 6.3% |
| 6 | DR.REDDY'S LABORATORIES LTD NAPROXEN TAB 500MG 500NAPROXEN AND ESOMEPRAZOLE MAGNESIUM DELA | $7.7M | 5 | 5.7% |
| 7 | AUROBINDO PHARMA LTD NAPROXEN 250MG TABLETS(NAPROXEN AUROBINDNAPROXEN 250MG TABLETS(NAPROXENO GENERISNAPROXEN TAB 500MG 500 | $6.3M | 3 | 4.7% |
| 8 | MARKSANS PHARMA LIMITED NAPROXEN TAB 500MG 500NAPROXEN AND ESOMEPRAZOLE MAGNESIUM DELA | $5.1M | 2 | 3.8% |
| 9 | AUROBINDO PHARMA LIMITED NAPROXEN 250MG TABLETS(NAPROXEN AUROBINDNAPROXEN 250MG TABLETS(NAPROXENO GENERISNAPROXEN TAB 500MG 500 | $3.8M | 5 | 2.8% |
| 10 | FOURRTS (INDIA) LABORATORIES PRIVATE LIMITED ANTALGIN 550MG NAPROXEN SODIUM TABLETS550MG PACK SIZE 4X10SNAPROXEN 250MG TABLETS(NAPROXEN AUROBINDANTALGIN 550MG (NAPROXEN SODIUM TABLETS | $3.6M | 4 | 2.7% |
| 11 | APOTEX RESEARCH PRIVATE LIMITED MYLAN NAPROXEN / ESOMEPRAZOLE MR 500 MGNAPROXEN SODIUM TABLETS USP 220MG TABS | $3.5M | 1 | 2.6% |
| 12 | DR REDDYS LABORATORIES LIMITED NAPROXEN TAB 500MG 500NAPROXEN AND ESOMEPRAZOLE MAGNESIUM DELAHARMLESS MEDICINE- NAPROXEN 500 MG TABLETS UNIT: 2X14 | $2.3M | 1 | 1.7% |
| 13 | FOURRTS I LABORATORIES PRIVATE LIMITED ANTALGIN 550MG NAPROXEN SODIUM TABLETS550MG PACK SIZE 4X10SNAPROXEN 250MG TABLETS(NAPROXEN AUROBINDANTALGIN 550MG (NAPROXEN SODIUM TABLETS | $1.9M | 2 | 1.5% |
| 14 | MEDREICH LIMITED HARMLESS MEDICINE- NAPROXEN 500 MG TABLETS UNIT: 2X14NAPROXEN TABLETS 500MGNAPROXEN 500MG TABLETS 2X14'S | $1.9M | 4 | 1.4% |
| 15 | S KANT HEALTHCARE LIMITED NALGESIN TABLETS 550MG (NAPROXEN SODIUMANTALGIN 550MG NAPROXEN SODIUM TABLETS550MG PACK SIZE 4X10SNAPROXEN 250MG TABLETS(NAPROXEN AUROBIND | $1.6M | 1 | 1.2% |
Related Analysis
Supplier Certification & Compliance Matrix
FDA, WHO-GMP, and EU GMP status for top Naproxen exporters
| Supplier | US FDA | WHO-GMP | EU GMP | ANDAs | Notes |
|---|---|---|---|---|---|
| Glenmark Pharmaceuticals Limited | Warning Letter, July 2025 | Unknown | Unknown | Not verified | FDA issued a warning letter citing significant CGMP violations at the Pithampur |
| Granules India Limited | Warning Letter, February | Unknown | Unknown | Not verified | FDA issued a warning letter for CGMP violations at the Gagillapur facility. |
| Aurobindo Pharma Limited | Warning Letter, June 2019 | Unknown | Unknown | Not verified | FDA issued a warning letter in 2019; compliance achieved by February 2023. |
| Unichem Laboratories Limited | Approved | Unknown | Unknown | 45 approved ANDAs | Holds 45 approved ANDAs and 75 US DMFs. |
| Mylan Laboratories Limited | Warning Letter, 2020 | Unknown | Unknown | Not verified | FDA issued a warning letter for CGMP violations at Unit 8 facility. |
| Dr. Reddy's Laboratories Limited | Warning Letter, 2015 | Unknown | Unknown | Not verified | FDA issued a warning letter for CGMP violations at Srikakulam facility. |
| Marksans Pharma Limited | Warning Letter, 2015 | Unknown | Unknown | Not verified | FDA issued a warning letter for CGMP violations at Goa facility. |
| Apotex Research Private Limited | Warning Letter, 2014 | Unknown | Unknown | Not verified | FDA issued a warning letter for CGMP violations at Bangalore facility. |
| Medreich Limited | Warning Letter, 2015 | Unknown | Unknown | Not verified | FDA issued a warning letter for CGMP violations at Bangalore facility. |
| S Kant Healthcare Limited | Warning Letter, 2015 | Unknown | Unknown | Not verified | FDA issued a warning letter for CGMP violations at Vapi facility. |
TransData Nexus reviewed the regulatory standing of 10 leading Naproxen exporters from India. 1 hold US FDA facility approvals, 0 maintain WHO-GMP certification, and 0 are EU GMP compliant. 9 suppliers have received FDA regulatory actions — buyers should verify current remediation status before placing orders. For regulated markets (US, EU, Australia), prioritise suppliers with active FDA or EU GMP approvals. For semi-regulated markets (Africa, ASEAN, Latin America), WHO-GMP certification is the minimum recommended standard.
Certification status compiled from publicly available regulatory databases including FDA Orange Book, WHO Prequalification database, and EMA GMP registry. Buyers should independently verify compliance status with the relevant regulatory authority before placing orders.
TransData Nexus Research · Mar 2026
Manufacturing Hub Analysis — Vendor Proximity
India's pharmaceutical clusters relevant to Naproxen sourcing
1Hyderabad — Bulk Drug Capital
Hyderabad, often referred to as the "Bulk Drug Capital of India," is a pivotal hub for the production of Active Pharmaceutical Ingredients (APIs). Companies like Dr. Reddy's Laboratories Ltd., headquartered in Hyderabad, have established themselves as major players in the Naproxen market. Dr. Reddy's operates a dedicated cGMP facility in Cuernavaca, Mexico, with a total capacity exceeding 1,500 metric tons for Naproxen API production. This facility ensures a robust supply chain and consistent quality, catering to global pharmaceutical needs.
2Ahmedabad-Vadodara — Formulations Hub
The Ahmedabad-Vadodara corridor in Gujarat is renowned for its focus on pharmaceutical formulations. Alembic Pharmaceuticals, based in Vadodara, exemplifies this specialization. The company manufactures and markets a range of pharmaceutical products, including formulations for therapeutic areas such as cardiology, dermatology, and infectious diseases. Their operations include manufacturing facilities in Gujarat and research and development centers in India and the United States.
3Mumbai-Thane-Raigad — Export Gateway
The Mumbai-Thane-Raigad region serves as a critical export gateway for pharmaceutical products. Cipla, headquartered in Mumbai, has a significant presence in this area. The company operates 34 manufacturing units across India and has a presence in over 80 countries. Cipla's extensive manufacturing capabilities and strategic location facilitate efficient export operations, contributing to India's prominence in the global pharmaceutical market.
4Baddi-Nalagarh — Tax Incentive Zone
The Baddi-Nalagarh region in Himachal Pradesh has emerged as a pharmaceutical manufacturing hub, largely due to favorable tax incentives. This area attracts numerous pharmaceutical companies seeking cost-effective production solutions. While specific data on Naproxen production in this cluster is limited, the region's overall contribution to India's pharmaceutical output is noteworthy.
5Sourcing Recommendations
- Diversify Supplier Base: Engage with multiple suppliers across different clusters to mitigate risks associated with regional disruptions.
- Assess Manufacturing Capabilities: Evaluate suppliers' facilities for compliance with international standards such as USFDA and EMA approvals to ensure product quality and regulatory adherence.
- Consider Export Experience: Prioritize suppliers with a proven track record in exporting to key markets like the United States, Canada, and Europe, ensuring familiarity with international logistics and regulatory requirements.
- Monitor Regulatory Compliance: Regularly review suppliers' adherence to Good Manufacturing Practices (GMP) and other relevant regulations to maintain consistent product quality and supply chain integrity.
Recent M&A, Collaborations & Capacity Expansions
Industry developments among top Naproxen exporters from India
Glenmark Pharmaceuticals Limited — Glenmark divests 75% stake in Glenmark Life Sciences to Nirma
In October 2024, Glenmark Pharmaceuticals Limited completed the divestment of a 75% stake in its subsidiary, Glenmark Life Sciences, to Nirma Limited for approximately ₹5,651 crore. IMPACT: This divestment may lead to a strategic realignment of Glenmark's focus, potentially affecting its Naproxen production and export capabilities.
Impact: This divestment may lead to a strategic realignment of Glenmark's focus, potentially affecting its Naproxen production and export capabilities.
Glenmark Pharmaceuticals Limited — FDA issues warning letter to Glenmark's Indore facility
On July 11, 2025, the FDA issued a warning letter to Glenmark Pharmaceuticals Limited's Indore facility, citing significant violations of Current Good Manufacturing Practice (CGMP) regulations, including inadequate investigation of batch failures. IMPACT: Regulatory scrutiny may disrupt Glenmark's production schedules, potentially impacting Naproxen exports.
Impact: Regulatory scrutiny may disrupt Glenmark's production schedules, potentially impacting Naproxen exports.
Glenmark Pharmaceuticals Limited, Granules India Limited, Unichem Laboratories Limited — Indian drugmakers recall products in US market
In September 2025, multiple Indian pharmaceutical companies, including Glenmark Pharmaceuticals, Granules India, and Unichem Laboratories, voluntarily recalled various drug products from the US market due to manufacturing issues such as deviations from CGMP, failed impurity and degradation specifications, dissolution issues, and label mix-ups. IMPACT: These recalls may affect the companies' reputations and could lead to increased regulatory scrutiny, potentially impacting Naproxen export volumes.
Impact: These recalls may affect the companies' reputations and could lead to increased regulatory scrutiny, potentially impacting Naproxen export volumes.
Common Questions — Naproxen Suppliers from India
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
Q Which naproxen supplier from India is the most reliable for bulk orders?
Based on shipment frequency and export consistency, MYLAN LABORATORIES LIMITED leads with 55 recorded shipments worth $23.3M. UNICHEM LABORATORIES LIMITED (276 shipments) and GLENMARK PHARMACEUTICALS LIMITED (303 shipments) are also established high-volume exporters.
Q How many naproxen manufacturers are there in India?
India has 192 active naproxen exporters with a combined export market of $133.8M across 3,414 shipments to 76 countries. The top 5 suppliers hold 60.2% of total export value.
Q What certifications should I verify?
Verify: WHO-GMP certification (most markets), US FDA approval (United States), EU GMP certificate (EU/EEA), and Free Sale Certificate from CDSCO. Always request a Certificate of Analysis (CoA) and Certificate of Origin (CoO).
Q What is the typical price range for naproxen from India?
Average FOB unit price: $15.88 per unit, ranging from $0.01 to $1678.68. Average shipment value: $39.2K.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Supplier Ranking: 192 verified Indian exporters of Naproxen ranked by capped export value from DGFT shipping bill records.
- 2.Export Value Analysis: Total export value aggregated from 3,414 individual shipping bill records. Values are FOB in USD.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
- 4.Market Concentration: Supplier market share and geographic reach analyzed across 76 destination countries.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
3,414 Verified Shipments
192 exporters tracked
Expert-Reviewed
By pharmaceutical trade specialists